WCLC 2024: The latest research results of the new generation HER2 ADC GQ1005 are unveiled
TECHNOLOGY
We are commited to develop differentiated next generation bioconjugate therapeutics through leveraging proprietary bioconjugation platform and integrating with other cutting-edge technologies, fulfilling urgent unmet needs.[More]